A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial to Evaluate the Safety and Efficacy of Eculizumab in Patients With Relapsing Neuromyelitis Optica (NMO)
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial to Evaluate the Safety and Efficacy of Eculizumab in Patients With Relapsing Neuromyelitis Optica (NMO)
The objectives of this time-to-event study were to assess the efficacy and safety of eculizumab as compared with placebo in participants with neuromyelitis optica spectrum disorder (NMOSD) who were anti-aquaporin-4 (AQP4) antibody-positive.
Key Inclusion Criteria:
Key Exclusion Criteria:
New York, New York 10016, United States
Gahanna, Ohio 43230, United States
Ciudad Autonoma, Buenos Aires, Buenos Aires 1425, Argentina
Ciudad Autonoma, Buenos Aires, Buenos Aires C1221, Argentina
Heidelberg, Baden-Wurttemberg 69120, Germany
Munich, Bavaria 81675, Germany
Nishinomiya-shi, Hyōgo 663-8501, Japan
Bunkyo-ku, Tokyo 113-8519, Japan
Ube-shi, Yamaguchi 755-8505, Japan
Kazan', 420021, Russia
Novosibirsk, 630067, Russia